Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone in Chinese Aceruloplasminemia Patients
NCT04184453Phase 1Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deferiprone in aceruloplasminemia, sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Change of pancreas MRI R2* at 3 months and Glycated hemoglobin at 3 months. Status: unknown.
02
Drugs
deferiprone
03
Conditions
aceruloplasminemia
Beyond the preview
Go deeper on NCT04184453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184453.